drugset / Trial / NCT07563972

Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors

NCT07563972 ↗

Phase 1 Recruiting 9 enrolled West China Hospital
Non-randomizedSequentialOpen-labelTreatment

Summary

The goal of this phase I clinical trial is to evaluate the safety and tolerability of intratumoral injection of mechanically reprogrammed macrophage-derived exosomes (MRMEs) in adults aged 18-65 years with advanced solid tumors who have failed, are ineligible for, or are intolerant of standard therapies.

Timeline

Start
2026-05-10
Primary completion
2027-03
Completion
2028-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mechanobiologically Reprogrammed Macrophage-Derived Exosomes Other / unclassified 1e+10 unknown Other
Subject Mechanobiologically Reprogrammed Macrophage-Derived Exosomes Other / unclassified 2.5e+10 unknown Other
Subject Mechanobiologically Reprogrammed Macrophage-Derived Exosomes Other / unclassified 5e+10 unknown Other

Indications